Lantern Pharma is an AI-focused oncology company that uses proprietary machine learning and data analytics to accelerate cancer drug discovery and development. The company has developed RADR®, a comprehensive platform containing over 200 billion oncology-focused data points and advanced algorithms that identify biomarker-driven patient populations and support both drug rescue of previously failed compounds and de novo drug development. The company's portfolio includes three clinical-stage small-molecule oncology candidates in development across non-small cell lung cancer, solid tumors, and hematological malignancies, and it plans to commercialize its AI platforms and RADR modules to pharmaceutical companies and researchers through subscription and licensing arrangements once its core drug candidates progress through clinical trials.